28 April, 2025Mainstay Medical announces exclusive coverage of ReActiv8® by Anthem Blue Cross/Blue Shield
28 April, 2025Purespring Therapeutics granted European Medicines Agency (EMA) orphan drug designation for PS-002 for the treatment of patients with primary IgA nephropathy (IgAN)
24 April, 2025CorWave announces successful completion of 6-month chronic in vivo study, paving the way for clinical trial initiation
15 April, 2025iOmx Therapeutics Receives Regulatory Approval of Clinical Trial Application for IOMX-0675
14 April, 2025ProQR strengthens leadership with appointments of CFO and CMO to support next phase of growth